Table 2.
Biomarker and Time of Collection | AUC (95% CI) to Predict 3-mo CKDa,b | AUC (95% CI) to Predict 3-mo HTNc,d |
---|---|---|
NGAL, ng/mg creatinine | ||
EV preinfusion | 0.55 (0.44 to 0.66) | 0.47 (0.31 to 0.62) |
EV postinfusion | 0.58 (0.47 to 0.69) | 0.48 (0.33 to 0.62) |
EV discharge | 0.65 (0.54 to 0.75)e | 0.56 (0.36 to 0.75) |
LV preinfusion | 0.53 (0.40 to 0.65) | 0.53 (0.36 to 0.70) |
LV postinfusion | 0.60 (0.48 to 0.72) | 0.48 (0.29 to 0.66) |
LV discharge | 0.57 (0.44 to 0.69) | 0.41 (0.23 to 0.59) |
KIM-1, pg/mg creatinine | ||
EV preinfusion | 0.62 (0.51 to 0.72)e | 0.38 (0.22 to 0.54) |
EV postinfusion | 0.59 (0.48 to 0.69) | 0.58 (0.43 to 0.73) |
EV discharge | 0.65 (0.55 to 0.76)e | 0.53 (0.34 to 0.71) |
LV preinfusion | 0.57 (0.45 to 0.70) | 0.49 (0.25 to 0.72) |
LV postinfusion | 0.61 (0.49 to 0.72) | 0.64 (0.45 to 0.82) |
LV discharge | 0.42 (0.30 to 0.55) | 0.59 (0.41 to 0.77) |
TIMP-2×IGFBP-7, (ng/ml) 2 /1000 | ||
EV preinfusion | 0.48 (0.38 to 0.59) | 0.70 (0.60 to 0.80)e |
EV postinfusion | 0.58 (0.47 to 0.69) | 0.59 (0.43 to 0.74) |
EV discharge | 0.58 (0.48 to 0.69) | 0.46 (0.29 to 0.62) |
LV preinfusion | 0.61 (0.49 to 0.72) | 0.61 (0.44 to 0.78) |
LV postinfusion | 0.60 (0.48 to 0.72) | 0.41 (0.25 to 0.57) |
LV discharge | 0.43 (0.31 to 0.55) | 0.47 (0.33 to 0.61) |
NGAL (ng/mg creatinine) and KIM-1 (pg/mg creatinine) | ||
EV preinfusion | 0.62 (0.52 to 0.73)e | 0.44 (0.29 to 0.60) |
EV postinfusion | 0.58 (0.47 to 0.69) | 0.57 (0.41 to 0.72) |
EV discharge | 0.67 (0.57 to 0.77)e | 0.57 (0.38 to 0.75) |
LV preinfusion | 0.52 (0.40 to 0.65) | 0.58 (0.38 to 0.79)f |
LV postinfusion | 0.62 (0.50 to 0.74) | 0.60 (0.40 to 0.80) |
LV discharge | 0.57 (0.45 to 0.70)f | 0.58 (0.40 to 0.77) |
NGAL (ng/mg creatinine) and TIMP-2×IGFBP-7 (ng/ml) 2 /1000 | ||
EV preinfusion | 0.59 (0.48 to 0.69) | 0.71 (0.62 to 0.80)f |
EV postinfusion | 0.57 (0.46 to 0.68) | 0.58 (0.42 to 0.74) |
EV discharge | 0.65 (0.54 to 0.76)e | 0.53 (0.35 to 0.72) |
LV preinfusion | 0.63 (0.51 to 0.75)e | 0.61 (0.43 to 0.78) |
LV postinfusion | 0.60 (0.48 to 0.72) | 0.52 (0.33 to 0.72) |
LV discharge | 0.50 (0.38 to 0.63) | 0.47 (0.33 to 0.60) |
KIM-1 (pg/mg creatinine) and TIMP-2×IGFBP-7 (ng/ml) 2 /1000 | ||
EV preinfusion | 0.62 (0.52 to 0.73)e | 0.70 (0.59 to 0.80)f |
EV postinfusion | 0.59 (0.48 to 0.70) | 0.61 (0.46 to 0.76) |
EV discharge | 0.65 (0.54 to 0.75)e | 0.50 (0.32 to 0.68) |
LV preinfusion | 0.66 (0.54 to 0.77)e | 0.69 (0.55 to 0.84)f |
LV postinfusion | 0.61 (0.49 to 0.73) | 0.65 (0.47 to 0.83) |
LV discharge | 0.46 (0.33 to 0.58) | 0.66 (0.49 to 0.83) |
Results stratified by time of cisplatin infusion. AUC, area under the curve; CI, confidence interval; EV, early visit; HTN, hypertension; IGFBP-7, insulin-like growth factor-binding protein 7; KIM-1, kidney injury molecule-1; LV, late visit; NGAL, neutrophil gelatinase-associated lipocalin; TIMP-2, tissue inhibitor of metalloproteinase-2.
For CKD analyses, including neutrophil gelatinase-associated lipocalin or kidney injury molecule-1, 118 patients were included. Early visit preinfusion: n=113, early visit postinfusion: n=113, early visit discharge: n=109, late visit preinfusion: n=89, late visit postinfusion: n=92, late visit discharge: n=85.
For CKD analyses, including tissue inhibitor of metalloproteinase-2×insulin-like growth factor-binding protein 7, 118 patients were included. Early visit preinfusion: n=117, early visit postinfusion: n=116, early visit discharge: n=111, late visit preinfusion: n=91, late visit postinfusion: n=93, late visit discharge: n=87.
For hypertension analyses, including neutrophil gelatinase-associated lipocalin or kidney injury molecule-1, 125 patients were included. Early visit preinfusion: n=120, early visit postinfusion: n=121, early visit discharge: n=116, late visit preinfusion: n=98, late visit postinfusion: n=99, late visit discharge: n=95.
For hypertension analyses, including tissue inhibitor of metalloproteinase-2×insulin-like growth factor-binding protein 7, 125 patients were included. Early visit preinfusion: n=124, early visit postinfusion: n=124, early visit discharge: n=118, late visit preinfusion: n=100, late visit postinfusion: n=100, late visit discharge: n=96.
Area under the curves: 95% confidence interval did not cross 0.50.
Statistically different than area under the curve of one biomarker alone as per the DeLong method.